PEDIATRICS Vol. 60 No. 6 December 1977, pp. 810-814
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asano, Y.
Right arrow Articles by Takahashi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asano, Y.
Right arrow Articles by Takahashi, M.

Clinical and Serologic Testing of a Live Varicella Vaccine and Two-Year Follow-up for Immunity of the Vaccinated Children

Yoshizo Asano M.D.1 and Michiaki Takahashi M.D.1

1 Department of Pediatrics, Chukyo Hospital, Nagoya, and the Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

A live varicella vaccine derived from the Oka strain was given to 181 children who had no history of vanicella and were seronegative by complement fixation (CF) and neutralization (NT) tests; 125 children were hospitalized and 54 were receiving steroid therapy. Overall, senoconversion was achieved in 85.1% of the children by the CF test and in 97.8% by the NT test. Clinical reaction consisting of mild fever and rash appeared in only two children.

One hundred seventy-nine of the vaccinated children were followed up by questionnaire and 51 were followed up serologically approximately two years later, at which time 10 of 51 (19.6%) were seropositive by the CF test and 50 of 51 (98.0%) by the NT test. Only one out of 80 children who had postvaccinal contact with varicella contracted mild vanicella 16 months after vaccination. None of the vaccinees developed herpes zoster.

These results suggest that this live varicella vaccine may safely and effectively be used for children with or without underlying diseases, including those receiving steroid thenapy, and that immunity of at least two years' duration is conferred upon the vaccinated subjects.

Submitted on March 1, 1977
Accepted on July 7, 1977




This article has been cited by other articles:


Home page
 J. Gen. Virol.Home page
J. M. Boname, H. M. Coleman, J. S. May, and P. G. Stevenson
Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant
J. Gen. Virol., January 1, 2004; 85(1): 131 - 135.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S A Skull and E E L Wang
Current topic: Varicella vaccination{---}a critical review of the evidence
Arch. Dis. Child., August 1, 2001; 85(2): 83 - 90.
[Full Text] [PDF]